Unusual Volume At Healthcare: VIVUS (NASDAQ:VVUS), Span-America Medical Systems (NASDAQ:SPAN), Cyberonics (NASDAQ:CYBX), RXi Pharmaceuticals Corp (NASDAQ:RXII)

Gilead Sciences GILD NASDAQ:GILD

VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.23. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 3.34% in last session and finished the day at $ 5.26. Traded volume was 2,821,422 shares in the last session and the average volume of the stock remained 3,442,280 shares. The beta of the stock remained 1.53. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Span-America Medical Systems, Inc. (NASDAQ:SPAN)reported its results for the second fiscal quarter ended March 29, 2014. Net income for the second quarter of fiscal 2014 was $891,000, or $0.30 per diluted share, compared with $1.2 million, or $0.41 per diluted share, in the second quarter of fiscal 2013. Net sales for the second quarter of fiscal 2014 were $14.7 million compared with $16.6 million in the second quarter of fiscal 2013. Span-America Medical Systems, Inc. (NASDAQ:SPAN)rose 1.29% percent to $ 21.25 Friday on volume of 16,099 shares. The intra-day range of the stock was $ 20.70 – 21.38. Span-America Medical Systems, Inc. (NASDAQ:SPAN)has a market capitalization of $ 62.92 million.

Cyberonics, Inc. (NASDAQ:CYBX)’s CFO Gregory Browne sold 1,500 shares of Cyberonics stock on the open market in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $61.61, for a total value of $92,415.00. Following the sale, the chief financial officer now directly owns 63,442 shares in the company, valued at approximately $3,908,662. Cyberonics, Inc. (NASDAQ:CYBX)’s stock on May 2, 2014 reported an increase of 2.68% to the closing price of $ 62.12. Its fifty two weeks range is $ 42.51 – 73.52. The total market capitalization recorded $ 1.67 billion. The overall volume in the last trading session was 672,305 shares. In its share capital, Cyberonics, Inc.(NASDAQ:CYBX) has 26.83 million outstanding shares.

RXi Pharmaceuticals Corp (NASDAQ:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI‑109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to build the Company’s ophthalmology franchise. On Friday, shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) advanced 6.62% to close the day at $ 3.38. Company return on investment (ROI) is -720.70% and its monthly performance are recorded as -22.83%. RXi Pharmaceuticals Corp (NASDAQ:RXII) quarterly revenue growth is -27.31%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone